RECRUITINGINTERVENTIONAL
Hesperidin RCT in MS
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
About This Trial
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Who May Be Eligible (Plain English)
Who May Qualify:
- Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Who Should NOT Join This Trial:
- Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Exclusion Criteria:
* Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Treatments Being Tested
DIETARY_SUPPLEMENT
Hesperidin
500 mg/day Hesperidin capsules for 12 weeks
DIETARY_SUPPLEMENT
Placebo
Matching maltodextrin capsules for 12 weeks.
Locations (1)
FHMLS, Nutrition Lab
Swansea, Wales, United Kingdom